# Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19

Study · id `cardio:ct-nct04373707` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04373707](<https://clinicaltrials.gov/study/NCT04373707>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04373707

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1000 participants.

## Technical summary

Registry record NCT04373707. Randomized; single masking; primary purpose prevention. Start 2020-05-13 (actual); primary completion 2021-04-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 1000 participants (enrolled count; ClinicalTrials.gov record NCT04373707, source copy `cardio:ctgov-nct04373707-2023-08-07`, retrieved 2026-10-31)
- Started: 2020-05-13 (actual) (ClinicalTrials.gov record NCT04373707, source copy `cardio:ctgov-nct04373707-2023-08-07`, retrieved 2026-10-31)
- Primary completion: 2021-04-29 (actual) (ClinicalTrials.gov record NCT04373707, source copy `cardio:ctgov-nct04373707-2023-08-07`, retrieved 2026-10-31)
- Completion: 2021-09-14 (actual) (ClinicalTrials.gov record NCT04373707, source copy `cardio:ctgov-nct04373707-2023-08-07`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT04373707, source copy `cardio:ctgov-nct04373707-2023-08-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04373707-2023-08-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19
- Acronym: COVI-DOSE
- Condition: COVID
- Condition: Thrombosis
- Condition: Pulmonary Embolism
- Condition: Deep Vein Thrombosis
- Intervention (Drug): Enoxaparin
- Intervention (Drug): Enoxaparin
- Lead sponsor: Central Hospital, Nancy, France
- Lead sponsor class: OTHER
- Collaborator: Ministry of Health, France
- Collaborator class: OTHER\_GOV
- Collaborator: Grand Est Region
- Collaborator class: UNKNOWN
- Collaborator: University Hospital of Saint-Etienne
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Enoxaparin (`core:enoxaparin`)
- Registry lists this organization as the lead sponsor: Central Hospital, Nancy, France (`cardio:org-central-hospital-nancy-france`)
- Registry lists this organization as a collaborator: Ministry of Health, France (`cardio:org-ministry-of-health-france`)

## Provenance

Content hash: 76aabd02a723d0c3443782690867677f0fe548c00702dc87a8a49b58e947a0fc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
